Fumonisin-induced hepatocarcinogenesis: mechanisms related to cancer initiation and promotion. by Gelderblom, W C et al.
Environmental Health Perspectives • VOLUME 109 | SUPPLEMENT 2 | May 2001 291
Investigations into the toxigenic properties of
Fusarium verticillioides (= Fusarium monili-
forme) have been the focus of many scientiﬁc
endeavors following the classic finding that
the fungus is responsible for natural out-
breaks of equine leukoencephalomalacia
(ELEM) (1,2). Many isolates of F. verticil-
lioides from different origins in southern
Africa were screened on a regular basis at the
Programme on Mycotoxins and Experimental
Carcinogenesis (PROMEC), Medical
Research Council, Tygerberg, South Africa,
in toxicity trials in ducklings and rats (3).
Comparative toxicity studies of the fungus in
different animal species led to the ﬁnding that
the major target organ differs in each species,
whereas certain organs, including the liver
and kidneys, appear to be affected consis-
tently to a greater or lesser degree (4). It was
proposed that the rat served as the best exper-
imental model to screen toxigenic isolates of
F. verticillioides for their potential to induce
different lesions in various animal species.
Several events following these initial studies
have made a major impact on the subsequent
research concerning the toxicologic effects of
this fungus in animals. One of these was the
finding that contamination of corn with
F. verticillioides was positively associated with
the incidence of human esophageal cancer in
the Transkei region of the Eastern Cape
Province, South Africa (5,6). Second, toxicity
screening of different F. verticillioides isolates
obtained from corn cultivated in a high-
incidence area of esophageal cancer induced
hepato- and cardiotoxic lesions in rats (4). The
induction of cirrhosis together with bile duct
and nodular hyperplasia was of particular
interest with respect to the potential carcino-
genic activity of different isolates of the fungus.
The possible link between occurrence of this
fungus on corn and the development of
esophageal cancer has initiated intensive inves-
tigations to characterize the toxic and carcino-
genic principle(s) that occur in corn, the major
dietary staple of humans in the Transkei. 
Toxicity and Carcinogenicity
Studies in Rats
Studies with Cultures of F. verticillioides
Strain MRC 826
An isolate of F. verticillioides designated strain
MRC 826, obtained from corn grown in a
high-incidence area of esophageal cancer in
Transkei, induced ELEM in horses and pro-
duced the potent mutagenic compound
fusarin C (3,4,7). Chronic feeding studies in
male BD IX rats with a freeze-dried corn cul-
ture (batch MRC 826B) of F. verticillioides at
dietary levels ranging from 2 to 4% in a
commercial rat feed caused liver cancer in
80% and ductular carcinoma in 63% of the
surviving rats after 450 days (8). An impor-
tant ﬁnding was that the hepatocellular carci-
nomas (HCCs) developed in cirrhotic livers
showing nodular hyperplasia. Another promi-
nent lesion was the concurrent development
of cholangio- or adenofibrosis, a lesion that
appears to develop from the proliferation of
hyperplastic epithelial cells, goblet cells, and
Paneth cells. The experiment was conducted
with both oven-dried (MRC 826, batch
9-20) and freeze-dried (MRC 826, batch B)
culture material and identical lesions were
induced; however, the degree of the effects
was higher with the freeze-dried material. It
was suggested that the causative principle(s)
was partially destroyed during the oven-
drying treatment at 45–50°C. This was of
particular interest because the mutagen
fusarin C, produced by the strain MRC 826,
was highly heat and light labile and not very
toxic acutely (7). Three pertinent issues
received attention in a subsequent chronic
feeding study (9) in rats using the same cul-
ture batch of the fungus (MRC 826, batch
B): whether the hepatocarcinogenicity was
related to the toxic effects of the fungal cul-
ture material; whether the nontoxic mutagen
fusarin C could be related to the carcinogenic
outcome; and whether the diet that was mar-
ginally deficient in certain vitamins and
lipotropes known to have protective effects
against esophageal cancer (10) could sensitize
rats to develop esophageal cancer when fed
low levels of the fungal culture.
We investigated the relative contributions
of fusarin C and toxicity to the carcinogenic
effects of the fungus in the liver by including a
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nontoxic strain of F. verticillioides, designated
MRC 1069, that produces three times more
fusarin C than strain MRC 826 (9). We used
a semisynthetic diet marginally deficient in
some vitamins and micronutrients to evaluate
a possible synergistic effect between nutri-
tional deﬁciencies and the fungal culture for
the induction of esophageal cancer (Table 1).
Most lesions found in the rats fed a dietary
level of 0.5% of the culture material of MRC
826, batch B, included a high frequency of
neoplastic nodules (21/21), ductular hyper-
plasia (21/21), adenoﬁbrosis (19/21), cholan-
giocarcinomas (8/21), and HCC (2/21) that
metastasized to the lungs. Liver sections of
85% of the animals showed marked increases
in the presence of gamma glutamyl transpep-
tidase positive (GGT+) foci and/or nodules.
Unlike results in the previous study (8), very
little ﬁbrosis, except in association with ade-
nofibrosis, was noticed in the liver, presum-
ably because of the low dietary levels of the
culture material used. Basal cell hyperplasia
occurred in 12/21 rats fed culture material of
strain MRC 826 (batch B), whereas one rat
developed an esophageal papilloma. Very few
lesions occurred in the liver of the rats fed
culture material of MRC 1069 despite its
being fed at a dietary level of 5%. Mild duc-
tular hyperplasia was present (18/22); one rat
had a focus of cholangioﬁbrosis and another
presented with a neoplastic nodule. Fatty
acid changes occurred in the treated rats of
both groups. Hepatocytes in the treated and
control rats were prominently loaded with
glycogen, presumably caused by the high car-
bohydrate content of the diet used. 
When comparing with the ﬁrst experiment
(8), we must consider several aspects. A clear
dose–response effect with respect to hepato-
toxicity and carcinogenicity became appar-
ent, suggesting that the hepatotoxicity is
related to cancer development by the fungus
in the liver of rats. Fusarin C was clearly not
involved in the carcinogenicity of the fungus
because culture material F. verticillioides
strain MRC 1069, containing at least 3 times
as much fusarin C and fed at a dietary level
10 times higher than that of MRC 826, pro-
duced only a few neoplastic lesions in the
liver. The basal cell hyperplastic lesions failed
to progress to neoplasia despite the fact that
the diet contained marginal levels of
lipotropes and some vitamins. 
Following these long-term studies with
fungal culture material in South Africa, a
feeding study in male Fischer 344 rats
showed that corn naturally contaminated
with F. verticillioides and associated with a
ﬁeld outbreak of ELEM in the United States
induced nodules, adenofibrosis, and cholan-
giocarcinomas in the liver after 4 to 6 months
(11). Although the corn-only diet was
deficient in many vitamins and lipotropes,
the lesions were very similar to those
described by Marasas et al. (8), which were
induced by F. verticillioides strain MRC 826
in male BD IX rats fed a nutritionally bal-
anced diet. The early appearance of the
lesions in the liver of the rats obtained by
Wilson et al. (11) seems related to dietary
deficiencies, as discussed above. This study
further strengthened the hypothesis that the
causative toxic principle(s) responsible for
ELEM in horses and the hepatotoxicity/car-
cinogenicity in rats could be identical. Studies
of the carcinogenic effects of fusarin C in a
short-term cancer initiation/promotion
model indicated that culture material of
F. verticillioides strain MRC 826 exhibited
cancer-promoting activity when using
diethylnitrosamine (DEN) as a cancer ini-
tiator and the induction of GGT-positive
foci and/or nodules as end points (12).
Subsequently, several other strains of the fun-
gus, isolated from a high-incidence area of
esophageal cancer in Transkei, were screened
for cancer-promoting activity in a modified
version of the resistant hepatocyte rat liver
model (13). As described above, DEN was
used as a cancer initiator while the culture
material of the different strains was fed at a
dietary level of 5% for 21 days during promo-
tion with the induction of GGT-positive foci
used as end point. Three other strains of
F. verticillioides in addition to strain MRC
826 exhibited cancer-promoting activity, and
a significant correlation was found between
toxicity and the cancer-promoting activity. As
discussed above, this study also suggested that
the compound(s) responsible for the toxic
and carcinogenic activity could be identical.
Studies with Fumonisin B1 Isolated
from F. verticillioides Strain MRC 826
Long-term studies. The fumonisin B (FB)
mycotoxins were originally isolated (14) using
the short-term cancer initiating/promoting
model described above and their chemical
structures were determined (15). Information
about the carcinogenic effects of FB1, the main
fumonisin produced by F. verticillioides,
obtained from a short-term study (14) sug-
gested that this mycotoxin could effect both
cancer initiation and promotion, and hence
could act as a complete carcinogen. Cancer ini-
tiation and promotion were associated with a
toxic effect characterized with the proliferation
of bile ductules, ﬁbrosis, and nodular regenera-
tion similar to those described for F. verticil-
lioides MRC 826 in male BD IX rats (16,17).
Dosing of horses proved that FB1 caused the
neurotic syndrome ELEM (18). These investi-
gations conﬁrmed the previous hypothesis that
the compound responsible for ELEM in horses
was also responsible for hepatotoxicity and
hepatocarcinogenicity in rats (4). These
ﬁndings led to carcinogenicity testing of FB1
in male BD IX rats performed with the culture
material of strain MRC 826 using a marginally
deﬁcient diet, as described by Jaskiewicz et al.
(9) and Van Rensburg et al. (10). 
When male BD IX rats were fed FB1 at 50
mg/kg diet, regenerative nodules and cholan-
giofibrosis occurred from 6 months onward
(19). The rats that were sacriﬁced or that died
from 18 months until 26 months, when the
experiment was terminated, suffered from
micro-and macronodular cirrhosis with large
expansive nodules of cholangiofibrosis.
Histologic changes inside the regenerative
nodules varied and included fatty changes,
hyaline droplet degeneration, necrosis, and
areas with a ground-glass appearance that
stained positive for GGT. Of the rats that
were killed between 18 and 26 months, 66%
developed HCC; in 4 rats this metastasized to
the kidney, heart, and lungs. Cholangio-
fibrosis—manifested as irregular ductlike
structures lined with an epithelium consisting
of large columnar cells and numerous goblet
cells—occurred in 100% of the rats killed
between 18 and 26 months. Lesions in the
kidneys consisted of diffuse interstitial lym-
phocytic nephritis and mild membranopro-
liferative glomerulonephritis and were more
pronounced in the rats killed at 26 months.
Most of the lesions observed in the liver and
kidneys of the rats fed FB1 (19) were also
induced by culture material of strain MRC
826, except that the esophageal basal cell
hyperplasia and cardiac lesions induced by the
culture material (8) were not present. Other
compounds present in the fungal culture
material may cause these lesions, either sepa-
rately or synergistically with the fumonisins.
However, it was shown that FB1 caused the
hepatotoxic and hepatocarcinogenic effects of
the fungal culture material in male BD IX
rats. In a subsequent experiment, low dietary
levels of FB1 were fed to male BD IX rats to
establish dose–response effects with respect to
cancer development in the liver (20). In short,
male BD IX rats were fed a semipuriﬁed diet
containing 1, 10, and 25 mg FB1/kg diet over
a period of 24 months. Detailed feed intake
profiles were monitored to calculate FB1
intake proﬁles during the course of the experi-
ment. No HCC or cholangiofibrotic lesions
were noticed in any of the rats terminated
between 18 months and 24 months. The
major lesions in the liver of the rats fed the
high-dose FB1 diet [25 mg FB1/kg (Table 1)],
consisted of anisokaryosis (13/17), neoplastic
nodules (9/17), oval cell proliferation (2/17),
bile duct hyperplasia (3/17), lobular distortion
and portal fibrosis (5/17), and ground-glass
foci (5/17), whereas the livers of all the rats
terminated at 26 months contained positive
foci (11/11) of the placental form of
gluthathione S-transferase (GSTP). In the rats
fed the 10 mg FB1/kg diet, fewer lesions
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appeared and only mild toxic lesions occurred
in the livers of the 1 mg FB1/kg dietary group.
The data indicate that a threshold exists and
that a chronic toxic effect is required for FB1-
induced hepatocarcinogenesis. The results of
these toxicity and carcinogenicity studies in
rats, together with estimated exposure levels,
were used to determine risk-assessment
parameters for fumonisins in humans (21). 
Since the discovery of the fumonisins in
1988, sensitive analytic detection techniques
have been developed (22), which have
enabled the retrospective estimation of the FB
intake in the initial long-term experiment
perfomed by Marasas et al. (8) and subse-
quently by Jaskiewicz et al. (9). These calcu-
lated data and comparisons with the
long-term studies in rats, using puriﬁed FB1
(19,20), are summarized in Table 2. Cancer
induction by the fumonisins occurs in the
presence of adverse hepatotoxicity, including
cirrhosis, cholangioﬁbrosis, and oval cell pro-
liferation (Table 2). An average dietary intake
of 0.08 mg FB/100 g body weight (bw)/day
induced mild toxic effects with 50% of the
rats having neoplastic nodules in the liver; an
average intake of 0.16 mg FB/100 g bw/day
causes liver cancer in 55% of BD IX male rats
over a period of approximately 2 years.
Dietary considerations. Comparisons of
the semipurified diet used in the chronic
feeding studies with culture material of MRC
826 (8,9) and FB1 (19) and the synthetic
AIN 76 diet (23) used in subsequent experi-
ments (17) are shown in Table 1. The semi-
puriﬁed diet was developed by Van Rensburg
et al. (10) to investigate the role of a diet low
in micronutrients on the development of
esophageal cancer in rats. The rationale behind
the study was to evaluate the role of simulated
human diets involving corn and wheat, which
are invariably used as a main source of food in
high-incidence areas for esophageal cancer, on
the development of esophageal tumors in
rats. The supplementation of marginally
deficient corn and wheat diets with various
combinations of nicotinic acid, riboflavin,
zinc, magnesium, molydenum, and selenium
reduced the numbers of esophageal papillomas
in rats (10). Indigenous African grains
(sorghum and millet) also signiﬁcantly reduced
the incidence of esophageal papillomas com-
pared to the corn-based diet (10). The nutri-
tional composition of the semipurified diet
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Table 1. Comparison of dietary compositiona of AIN 76 diet with the semipuriﬁed diet used in fumonisin B1 feeding
studies. 
AIN-76 Semipuriﬁed AIN-76 Semipuriﬁed
Protein (g/kg) 214.3 109 Vitaminsb
Soy protein 30 Thiamin (mg) 6.4 3.9
Casein 200 10 Riboﬂavin (mg) 6.1 3.55
Egg albumin 10 Nicotinic acid (mg) 31.1 32
Corn meal 59 Vitamin B6 (mg) 7.1 0.6
Methionine 3 1.91 Folate (mg) 2 0.5
Total CHO (g/kg) 592 659.1 Vitamin B12 (µg) 10 8
Corn starch 216.7 750 Pantothene (mg) 16.8 3
Sucrose 216.7 Biotin (mg) 0.2 0.1
Glucose 216.7 111.25 Vitamin A (IU) 4,005 16,672
Dextrin 54.3 Vitamin D (IU) 1,000 250
Vitamin E (mg) 79.7 41.33
Total Fat (g/kg) 46.4 47.6 Vitamin K (mg) 5 2.95
Saturated 5.9 6.33 Choline 2 0.7
MUFA 9.0 11.7
PUFA 29.3 27.0 Mineralsc
Sunﬂower seed oil (g) 50 30 Calcium 5,100 515
Iron 48 17.3
Energy Magnesium 604 488
Kcal 3,779 3,448 Phosphorus 4,264 1,133
KJ 15,820 14,426 Potassium 3,925 2,307
Sodium 1,245 1,028
Fibre (g/kg) 55.4 37.2 Zinc 46 20.8
Copper 5.7
Abbreviations: CHO, carbohydrate; KJ, kilojoules. aComposition analyses performed using the MRC Food Composition Tables (80).
bmg/kg or units/kg. cmg/kg AIN-76 (23); semipuriﬁed diet (18). 
Table 2. Comparison of body weight gains, total FB intake, and histologic ﬁndings between different long-term experiments with culture material of F. verticillioides and puriﬁed
FB1 in male BD IX rats. 
FCM intake FB intake
Body weight FCM (mg/100 g  (mg/100 g  Duration Total intake Major histologic
Reference Initial (g) Final (g)  Gain (g) (% in diet) bw/day) bw/day) (days) (mg/100 g bw) lesions in the liver
Marasas  63.5 ± 4.7  290.1 ± 46.8 226.6 ± 47.3 4 0.13 0.69 288 198.33 Cirrhosis (20/20)
et al. (8) 2 0.06 0.32 606 195.62 Adenoﬁbrosis (19/20)
Total: 394.95 Ductular carcinoma (10/20)
Control 64.7 ± 4.8 370.8 ± 71.8 306.1 ± 70.2 0.0005 894 0.45 HCC (12/20)
Basal cell hyperplasia (11/15)
Jaskiewicz  113.9 ± 4.7 359.8 ± 78.0 246.0 ± 77.6 0.25 0.01 0.04 211 9.08 Neoplastic nodules (18/21)
et al. (9) 0.50 0.02 0.09 311 26.8 GGT-positive foci (18/21)
0.75 0.02 0.13 81 10.46 Fatty change (21/21)
0.50 0.02 0.09 266 22.90 HCC (2/21)
Total: 70.21 Ductular hyperplasia (21/21)
Control 113.6 ± 5.1 483.6 ± 88.4 370.0 ± 87.2 0.0005 869 0.39 Adenoﬁbrosis (19/21)
Cholangiocarcinoma (8/21)
Gelderblom  68.6 ± 1.9 416.0 ± 38.2 347.5 ± 38.01 50 mg FB1/kg diet 0.160 780 124.8 Cirrhosis (15/15)
et al. (19) Regenerative nodules (15/15) 
Cholangioﬁbrosis (15/15)
Control 68.1 ± 2.7 517 ± 108.8 448.9 ± 107.4 HCC (10/15)
Gelderblom  98.5 ± 7.1 445.1 ± 88.9 346.6 ± 89.9 25 mg FB1/kg dieta 0.080 690 55.20 Anisokaryosis (13/17)
et al. (20) 98.4 ± 7.4 474.4 ± 71.8 376.0 ± 71.3 10 mg FB1/kg diet 0.032 690 22.08 Hyperplastic nodules (9/17)
101.4 ± 6.3 483.6 ± 114.7 382.2 ± 115.0 1 mg FB1/kg diet 0.003 690 2.21 Oval cell proliferation (2/17)
Control 95.06 ± 9.2 423.8 ± 107.7 328.7 ± 105.2 0.22 g FB1/kg 0.001 690 0.35 Bile duct hyperplasia (3/17)
Portal ﬁbrosis (5/17)
Ground-glass foci (7/17)
GSTP foci (11/11)
FCM, Fusarium culture material. aHistologic changes recorded in the high-dose group (20).
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used in the long-term experiments differs
from that of the AIN 76 (23) developed for
rats in several respects. These differences
included low protein content and marginal to
marked deﬁciencies in lipotropes (2- to 3-fold
lower), vitamins (2- to 10-fold lower), and
minerals (2- to 10-fold lower). The caloric
contents of the two diets were similar. It is
well recognized that diet plays a major role in
the induction and spontaneous development
of cancer in experimental animals (24). The
semipurified diet used in the long-term
studies, therefore, could have had an impor-
tant influence on the outcome of liver and
esophageal cancer development in the male
BD IX rats—for example, the methionine
content of the semipuriﬁed diet was margin-
ally lower whereas the folate levels were four
times lower. Low levels of the lipotropes,
methionine, and choline are involved in
cancer development of many organs includ-
ing the liver (25). In addition to folic acid,
these lipotropes play important metabolic
roles in the utilization of methyl groups (24). 
Short-term studies. Several short-term
cancer models, using rat liver, exist to study
the underlying mechanisms of cancer devel-
opment by genotoxic carcinogens (26).
Because FB1 is a complete carcinogen in the
liver, subsequent studies were directed to
investigate the cancer-initiating and -promot-
ing potential of this apparently nongenotoxic
mycotoxin. The cancer-promoting activity of
F. verticillioides was first demonstrated in
male BD IX rats (13) and, as discussed above,
used to purify the different structurally
related fumonisin analogues. The basic con-
cepts underlying the processes of initiation
and promotion by fumonisins are discussed
in detail elsewhere (21,27) and are based on
the “resistant hepatocyte” model developed in
the liver by Farber (28). In short, there are
two basic sequences of which the first is the
production or appearance of hepatocytes with
a so-called “resistant” phenotype that makes
them resist the growth-inhibitory or toxic
effects of many carcinogens. Genotoxic car-
cinogens rapidly (within several minutes or
hours) induce this new phenotype (29),
whereas nongenotoxic carcinogens such as
clofibrate (30), FB1, and a choline-deficient
diet (25) induce a similar phenotype but over
a period of several weeks. The induction of
this phenotype is complex, and although a
mutation-like event is generally considered an
important step, this supposition is critically
questioned (31). For the ultimate cancer to
develop, the altered or initiated cell ﬁrst must
be stimulated to grow during promotion or
selection. During this process, called differen-
tial inhibition, the initiated cell proliferates in
an environment created by the promoter that
inhibits the growth of the surrounding
normal hepatocytes (32). 
Cancer initiation. Initial studies on the
cancer-initiating potential of the FB mycotox-
ins were performed in male Fischer rats fed a
puriﬁed basal diet (16). Two different proto-
cols were used. In the ﬁrst, FB1 was fed in the
diet (1 g FB1/kg diet) for 26 days followed by
partial hepatectomy. Selection occurred 2
weeks later by 2-acetylaminoﬂuorene/carbon
tetrachloride (AAF/CCl4), and the rats were
sacriﬁced after an additional two weeks. The
second protocol consisted of partial hepatec-
tomy (PH) followed by single gavage dosages
of FB1 at various time points before or after
PH. The latter regimen is the classic protocol
for evaluating the cancer-initiating potential
of genotoxic carcinogens (28). Histologic
changes induced by feeding FB1 in the diet for
26 days were similar to those described for
BD IX rats and included the generation of
early hepatocyte nodules and mild to moder-
ate bile duct proliferation. After the promot-
ing treatment, three to ﬁve hepatocyte nodules
were visible macroscopically in the liver; the
number of GGT positive foci was also signiﬁ-
cantly increased compared to the controls. In
contrast to this ﬁnding, neither FB1 nor FB2
exhibited any cancer-initiating activity during
the gavage treatment before or after PH
(second protocol). 
Subsequent studies in male Fischer rats fed
the AIN 76 diet focused on dosage studies in
relation to the initiating and promoting
potential of the mycotoxin (17,33). Initiation
depended on both the dosage and the dura-
tion of the treatment. A dose of 29.7 mg
FB1/100 g bw over 7 days did not effect initi-
ation, whereas the same dosage over 21 days
did. Initiation by FB1 also depended on the
induction of a hepatotoxic effect together with
compensatory or regenerative cell prolifera-
tion, a prerequisite for initiation (34). FB1
also appears to be a mitoinhibitor of normal
hepatocytes; a dietary treatment of 250 mg
FB1/kg bw for 3 weeks (16) or a single gavage
dose of 50 mg/kg bw (33) inhibits liver regen-
eration induced by PH. Thus, a balance seems
to exist between the induction and inhibition
of hepatocyte regeneration, and the effect on
cancer initiation may depend on which of
these two processes prevails at a speciﬁc time.
For example, a total dosage of 29.7 mg
FB1/100 g bw over 7 days is likely to create a
strong inhibitory effect on cell proliferation
and therefore will not support the process of
cancer initiation. However, the same dosage
administered over 21 days is likely to support
regenerative cell proliferation as a result of
FB1-induced hepatotoxicity, which then will
support cancer initiation (17). The latter con-
cept is not new; initiation by many genotoxic
hepatocarcinogens is potentiated either by use
of a toxic dosage that stimulates hepatocyte
regeneration or by the introduction of PH
during the initiating regimen. In combination
with PH, which synchronizes the entry of liver
cells into the S-phase by approximately 18 hr,
cancer initiation by a genotoxic carcinogen
could be effected at very low doses when
introduced at this stage (35). The same holds
true for initiation by the fumonisins, except
that the whole process occurs at a far slower
rate, probably because the FB1-induced cell
proliferation is counteracted by its mitoin-
hibitory effect, producing a much smaller
yield of initiated hepatocytes. In addition, a
recent study indicated that FB1 induced apop-
tosis (36), which has been suggested to reduce
the number of initiated cells in the liver (37).
Another aspect that could determine the
kinetics of the initiating step is the nature of
the event(s) leading up to the induction of
the initiated hepatocytes as a result of FB1
treatment. The nature of initiation is of par-
ticular interest with respect to FB1 because
the compound appears not to exhibit any
mutagenic or genotoxic effects in different in
vivo and in vitro tests (16,38). However,
Knasmuller et al. (39) reported that FB1 as
well as the mycotoxins moniliformin and
deoxynivalenol exhibited clastogenic effects
(chromosomal aberrations) at concentrations
from 1.4 to 144 µM in primary hepatocyte
cultures. At these concentrations FB1 reduced
the mitotic index and the induction of
micronuclei markedly to signiﬁcantly. These
data suggested that FB1 might exhibit some
genotoxic effects. It was postulated that lipid
peroxidation could play a role in the chromo-
somal breakage caused by the accumulation
of polyunsaturated fatty acids in primary rat
hepatocytes after exposure to FB1 (40).
Because cytotoxic effects and lipid peroxida-
tion occur only at high concentrations of FB1
(> 75 uM), the induction of chromosomal
aberrations at levels of 1.4 and 14 µM need
to be investigated further to clarify whether
FB1 is directly or indirectly responsible for
chromosomal strand breaks. The disruption
of sphingolipid metabolism is effected maxi-
mally at these concentrations (41), with the
accumulation of sphinganine known to affect
cell growth and differentiation (42).
However, for the purpose of the present
review, the fumonisins will be regarded as not
causing direct DNA damage (mutations).
As mentioned above, the role of lipid
peroxidation during cancer initiation in rat
liver must be considered (17) because rela-
tively high cytotoxic dosages over long time
periods are required. Recent investigations
indicated that FB1 induces lipid peroxidation
in cell membrane preparations (43) and iso-
lated rat liver nuclei (44) and in primary rat
hepatocytes and rat liver in vivo (45). When
egg yolk phosphatidylcholine (PC) bilayers
were used (43), FB1 increased the rate of oxi-
dation, free radical production, and lipid per-
oxidation, thereby disrupting membrane
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structure and permeability. These effects were
noticed at high concentration levels—
between 1 and 10 mM FB1—raising some
doubts about inducing similar effects in vivo.
Cawood et al. (46) showed that when radiola-
beled FB1 is used, the compound is tightly
associated with plasma and microsomal
membranes. However, a speciﬁc binding site
for the fumonisins has not yet been character-
ized. Nuclear membrane lipid peroxidation
with concomitant DNA strand breaks
occurred in isolated rat liver nuclei treated
with FB1 in vitro at concentrations ranging
from 40 to 300 µM (44). The formation of
hydroxy and the subsequent formation of
peroxyl radicals in the vicinity of nuclear
material was proposed to cause DNA strand
breaks. It was further postulated that metal
ions, specifically iron, endogenously associ-
ated with cellular DNA could be important
sites for metal-catalyzed oxidative DNA dam-
age. In vitro studies in primary hepatocytes
showed that lipid peroxidation is effected in a
dose-dependent manner closely associated
with cytotoxicity induced by FB1 (45).
Although α-tocopherol prevented lipid per-
oxidation by FB1, cytotoxicty was not com-
pletely abolished, indicating that lipid
peroxidation is not solely responsible for the
cytotoxic effects and could be secondary to
cell cytotoxicity. Except for halogenated
hydrocarbons such as carbon tetrachloride,
oxidative stress and the resultant lipid peroxi-
dation seem to occur as a result of cell injury
induced by toxins (47). At low levels of expo-
sure (75 µM), FB1 also enhanced the suscep-
tibility of hepatocytes to undergo lipid
peroxidation induced by cumene hydroperox-
ide, probably via the accumulation of poly-
unsaturated fatty acids in primary hepatocytes
(40). In a recent study in rats fed a dietary
level of 250 mg FB1/kg diet, with or without
dietary iron loading, FB1 augmented iron-
induced lipid peroxidation in the liver (48).
Observations from in vivo feeding studies
support the results from in vitro studies that
lipid peroxidation occurs in a dose-dependent
manner associated with a hepatoxic effect.
Lipid peroxidation appeared to be a secondary
effect rather than a causative mechanism of
FB1-induced hepatic injury (45). Puriﬁcation
of membranal fractions indicated that FB1 sig-
niﬁcantly (p < 0.05) increased lipid peroxida-
tion in plasma and microsomal membranes at
a dietary level of 250 mg/kg, and it was
enhanced (not signiﬁcantly) in the mitochon-
drial and nuclear membranal fractions.
Oxidative damage could well be an important
initial event and in addition to the inhibitory
effect on cell proliferation, could explain the
slow kinetics of the initiating step. Apoptosis
also must be considered because it becomes an
important biologic phenomenon at high
exposure levels of fumonisins (36,49) and
because it is known to remove the genetically
altered initiated cells in the liver (50).
With respect to the cancer-initiating
potency of FB1 (45), cancer initiation of the
choline-deficient diet occurred only after 9
weeks, preceded by lipid peroxidation and a
hepatotoxic effect (25). The peroxisome
proliferator cloﬁbrate (30) also causes cancer
initiation after prolonged feeding of several
weeks. Because FB1 is considered a weak or
slow cancer initiator, the compound may
have a strong effect on postinitiation events
such as cancer promotion (17). Because the
fumonisins occur naturally at relatively low
dietary levels compared to the levels that ini-
tiate cancer in rats, future research should
focus on the events related to later phases of
cancer development, including promotion
and progression. 
Cancer promotion. As discussed above, the
process of promotion represents an important
phase during which the initiated cells are clon-
ally expanded into hepatocyte nodules by a
process known as differential inhibition
(28,32). Although other mechanisms of the
clonal expansion of the initiated hepatocyte
have been proposed, considerable evidence
exists to support a selection process whereby a
few resistant hepatocytes proliferate in an
environment where the proliferation of nor-
mal cells is inhibited (32). A compound is
called a cancer promoter if it can create such
an environment, and studies of fumonisins
indicate that a similar hypothesis could be
developed for the cancer-promoting property
of these compounds. This growth selection of
resistant hepatocytes has been recognized as a
property of different cultures of F. verticil-
lioides (12,13) and was successfully used to
develop a bioassay for the puriﬁcation of the
fumonisins. Initial studies suggested that
hepatotoxicity was associated with the cancer-
promoting potential of this mycotoxin (13). A
recent study showed that cancer promotion,
unlike initiation, was effected at relatively low
dietary levels (50 mg FB1/kg diet) in the
absence of excessive hepatotoxicity (33). The
cancer-promoting activity of FB1 was also
associated with an inhibitory effect on hepato-
cyte proliferation. This suggested an induction
of a growth differential whereby the growth of
the resistant initiated cells is promoted and
that of normal cells inhibited. Inhibition of
cell growth occurs in many cell culture sys-
tems (51) and in rat liver in vivo under differ-
ent experimental conditions involving PH. A
dietary level of 250 mg FB1/kg fed over 21
days signiﬁcantly inhibited regenerative hepa-
tocyte cell proliferation in hepatectomized
male Fischer rats after 24 hr (17). Three days
after PH the level of DNA synthesis was sig-
nificantly higher in the FB1-treated group,
whereas at 7 days there was no difference. FB1
seems to delay hepatocyte regeneration in a
reversible manner. Even a single gavage dosage
(50 mg/kg bw and higher) 6 hr after PH sig-
niﬁcantly inhibited DNA synthesis. Thus, the
inhibitory effect on cell proliferation is likely
to be an important determinant of cancer pro-
motion in rat liver. Many cancer promoters
such as 2-acetylaminoﬂuorene, phenobarbital,
orotic acid, and ciprofibrate inhibit the epi-
dermal growth factor (EGF)-induced mito-
genic response in primary hepatocytes (33).
This inhibitory effect—also known as mitoin-
hibition of the EGF response by FB1—has
been used to investigate possible mechanisms
involved during cancer promotion (41).
Binding of EGF to its receptor was not
affected in hepatocytes exposed for 12 hr to
FB1. The inhibitory effect was also reversible;
maximum inhibition seemed to occur late
during the G1-phase of the cell cycle.
Pretreatment of hepatocytes with FB1 only
marginally inhibited the EGF response, indi-
cating that there is very little memory after the
mycotoxin is removed. In vivo and in vitro
experiments suggest that FB1 behaves in a
manner similar to most cancer promoters in
inducing a growth differential that selectively
stimulates the outgrowth of initiated cells.
Although a mechanism for cancer initia-
tion has been proposed for FB1 (see above),
the process whereby FB1 creates a growth dif-
ferential in the liver that selectively favors the
growth of initiated cells still needs to be eluci-
dated. The ﬁnal part of this review focuses on
a mechanism that is likely to create such a
“promoting” environment to sustain the
process of differential inhibition. 
Altered Lipid Biosynthesis 
as a Possible Mechanism 
for Cancer Promotion by the
Fumonisins: A Hypothesis
General Introduction
The major constituents of cellular membranes
are the phospholipids, which contain fatty
acids as important constituents of the typical
bilayer structure (52). Essential fatty acids
(EFA) are normally linked to the 2 position of
the glycerol backbone of the phospholipids
and sometimes also to the 1 position. Free
cholesterol is closely associated with the fatty
acids and hence is an important mechanism in
determining membrane ﬂuidity. EFA consists
of the ω6 and ω3 derived from linoleic acid
(C18:2ω6) and α-linolenic acid (C18:3ω3)
respectively (Figure 1). A series of alternating
desaturations (which add a double bond) and
elongations (which add two carbon atoms) are
involved in the synthesis of the different long-
chained fatty acid metabolites. The desatura-
tion and elongation are not confined to the
metabolism of EFA; the saturated fatty acids
palmitic and stearic can also be converted to
long-chained fatty acids. Apart from the role
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of EFA as structural components of all
membranes, they are precursors of the
eicosanoids, prostaglandins, leukotrienes, and
other oxygenated derivatives.
In Vitro Studies in Primary Hepatocytes
Studies in primary hepatocytes indicate that
the incorporation of 14C palmitic acid
decreased in the total lipids and the neutral
lipids, triacylglycerol (TG), and the choles-
terol esters at a noncytotoxic concentration of
150 µM FB1 and at cytotoxic concentrations
of 250 µM and higher (40). In contrast, the
incorporation of radiolabel into phospho-
lipids increased with a concomitant increase
in the concentration level of PC and phos-
phatidylethanolamine (PE), whereas the total
cholesterol decreased. The concentration and
labeling of sphingomyelin (SM) decreased,
presumably as a result of the inhibitory effect
on the ceramide synthase, a key enzyme in
the sphingolipid biosynthetic pathway (53).
Fatty acid changes were restricted mainly to
PC and TG with a decrease in the relative
levels of C16:0 and the C16:1ω7 fatty acids
and C18:1ω9. Changes in polyunsaturated
fatty acids (PUFA) were restricted mainly to
an increase in C18:2ω6 in TG and PC;
C20:4ω6 also increased in both PC and TG.
These changes were observed in cytotoxic and
noncytotoxic dosage levels. As a result, the
PUFA increased in both PC and TG. The
increases in PC, PE, and PUFA are likely to
counteract the shift to a more rigid mem-
brane structure caused by the decrease in total
cholesterol. The increase of C18:2ω6 could
be related to the impairment of the ∆6 desat-
urase enzyme, the rate-limiting enzyme in
fatty acid metabolism (Figure 1), and the
increase in C20:4ω6 could be caused by the
disruption of prostaglandin biosynthesis by
inhibiting the cyclooxygenase enzyme. This
was supported by the ﬁnding that the inhibi-
tion of monooxygenase by ibuprofen also
inhibits the EGF mitogenic response (54). At
lower concentrations of FB1, the relative
levels of C20:4ω6 were unaffected, whereas
C18:2ω6 still increased, indicating that,
depending on the dosage, different effects
could be induced in primary hepatocytes.
This implies that the disruption of the ∆6
desaturase could be an important early event
that occurs in hepatocytes exposed to low
concentrations of FB1. The accumulation of
C20:4ω6 was effected at dosages that signiﬁ-
cantly inhibit the EGF response (41). The
inhibition of C20:4ω6 metabolism by FB1
was further strengthened by the following:
First, the addition of C20:4ω6 and C20:5ω3
to primary hepatocytes in the presence of
EGF respectively stimulates and inhibits the
mitogenic response; second, the mitoin-
hibitory effect of FB1 was counteracted by the
addition of prostaglandin E2 (54). Changes to
the fatty acid profiles of hepatocytes mem-
branes and speciﬁcally C20:4ω6 also effected
the mitogenic response. This was shown by
the addition of C20:5ω3, which inhibits the
EGF response presumably by replacing
C20:4ω6 from the membrane phospholipids.
The resulting formation of the prostaglandin
E3 series has fewer, even opposite, properties
from those of the prostaglandin E2 series that
are produced from C20:4ω6 (51). These
results suggest that C20:4ω6 is central to the
regulation of the EGF response in primary
hepatocytes. This was recognized earlier, as
the disruption of C20:4ω6 metabolism
affects the mitogenic response of EGF and
hepatocyte growth factor (HGF) in primary
hepatocytes (55).
In Vivo Studies in Rats
In vivo studies indicate that FB1 disrupted
lipid biosynthesis differently from that in the
in vitro studies (56). In contrast to the in vitro
studies, the major changes were associated
with both the PE and the PC phospholipid
fractions, and cholesterol increased in both the
serum and liver. In the short-term studies in
male Fischer rats, a dietary level of 250 mg
FB1/kg increased the PE level, whereas SM
decreased. No effect was noticed in the rats
that received the 50 and 100 mg FB1/kg diets.
However, in long-term studies using BD IX
rats, dietary levels of 1, 10, and 25 mg/kg
increased the PE levels in the liver. Fatty acid
analyses of the PE and PC fractions of the
liver indicated that, as was shown in the in
vitro study, the relative level of C18:2ω6
increased in PE and markedly in the PC frac-
tion of the rats from the short-term study.
The level of C20:4ω6 was not altered,
although there was a marked decrease in the
PC fraction using the 250 mg/kg dietary level.
C22:5ω6, the end product in the n-6 meta-
bolic pathway, was reduced in PE in the liver
of the rats that received the 100 and 250
mg/kg diets. A similar pattern was noticed in
the liver of rats of the long-term study in both
the PC and PE fractions, but because of the
small numbers of rats (3 per group) used for
analyses, these changes were not significant.
However, analysis of the total fatty acid pro-
ﬁles of the liver, using a larger number of rats
per group (4 to 6 animals/group), indicated
that the relative levels of C18:2 increased.
Fatty acid analyses of serum PC of both the
short-term and long-term FB1 feeding studies
conﬁrm the observations obtained in the liver:
an increase in C18:2ω6 but a decrease in
C20:4ω6 and C22:5ω6 in the short-term (50
mg FB1/kg diet and higher) and long-term
(10 mg/FB1/diet and above) experiments.
With regard to the total fatty acid parameters,
the monounsaturated fatty acids (MUFA)
increased in PE, whereas the total n-6 and
PUFA decreased in PC. In the long-term
experiment, the MUFA increased in PC while
the n-3 fatty acids increased in PC and PE,
altering the n6/n3 ratio. The effect of FB1 on
the n-6 fatty metabolic pathway seems to rely
to a greater or lesser extent on the dietary level
of FB1, the length of exposure, the speciﬁc cel-
lular phospholipid fraction, and differences
between in vitro and in vivo experiments. 
Subsequently, the effects of different
dietary dosages (10, 50, 100, and 250 mg
FB1/kg diet) of FB1 fed for 21 days were eval-
uated on lipid metabolism in rat liver micro-
somal membranes (57). These dietary levels
of FB1 were used to investigate the cancer-
promoting potential of the fumonisins in
DEN-initiated rats (29). The major changes
associated with the microsomes were
increased levels of PC, phosphatidyl inositol
(PI), PE, and cholesterol. The levels of the
saturated fatty acids and MUFA, especially
C18:1ω9, increased significantly in the
treated groups (100 mg FB1/kg diet and
higher) in all the phospholipids except phos-
phatidyl serine (PS). The relative (%) and
absolute (µg) values of C18:2ω6 increased in
the PC, PI, PS, and PE phospholipid frac-
tions. C20:4ω6 showed a decrease in the rela-
tive values, whereas the absolute values
remained constant in PC, PI, and PS despite
the fact that the concentration of the phos-
pholipids increased in the high-dosage
groups. In PE, however, the relative value was
not altered. However, the absolute value of
C20:4ω6 in PE increased, presumably
because of the prominent increase (> 2￿) in
the level of PE compared to that of the other
phospholipids. A similar effect was noted
with C22:4ω6 and C22:5ω6 in PC and PE.
The relative values of the n-3 fatty acid,
C22:6ω3, also decreased in a dose-responsive
manner in all the phospholipids; the absolute
values remained the same except PE, where
they signiﬁcantly increased. The relative levels
of total PUFA were not altered; the absolute
levels increased (PC, PE, and PI) because of
Figure 1. Essential fatty pathways indicating the key
role of ∆6 desaturase enzyme and the fatty acids
involved in the synthesis of different prostaglandins. The
marked fatty acids (boxes) are likely to play a key role in
the development of hepatocyte nodules. 
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increased phospholipid concentrations. The
polyunsatured/saturated (P/S) fatty acid ratio
also decreased in the PC phospholipid frac-
tion because of alterations in the PUFA and
saturated fatty acid levels. Changes to mem-
branal environment of FB1 also expanded and
included the plasma, mitochondrial, and
nuclear membrane fractions of rat livers
exposed to 250 mg FB1/kg diet for 21 days.
Some differences exist in the lipid proﬁles of
the different membrane fractions with respect
to the effect of FB1 on the levels of choles-
terol and PC and PE. In the plasma mem-
brane and nucleus, only PE significantly
increased; PC, SM, and cholesterol were
unchanged. The mitochondrial membrane
structure was also altered differently from the
plasma membrane. The level of PE increased,
PC and SM decreased, and cholesterol
remained unchanged. The fatty acid patterns
were similar, with minor differences between
PC and PE—e.g., PUFA decreased in PC
(both the relative and absolute values),
whereas in PE the relative value decreased
and the absolute value increased. The
absolute values of the saturated fatty acids
and MUFA increased, causing a decrease in
the P/S ratio of PC and PE and suggesting a
less ﬂuid mitochondrial membrane.
It can be argued that some of these
changes can be related to the hepatotoxic
effects induced by FB1 in the liver. Apart
from cancer promotion, the toxic effects are
closely related to cancer initiation by the
fumonisins, making it difficult to associate
specific changes in lipid metabolism with
cancer induction at this stage. However, a
characteristic fatty acid pattern seems to
emerge in the livers of rats exposed to dietary
levels of FB1 that effect both cancer initiation
and promotion. These include the following:
First, an increase in saturated fatty acids and
MUFA (C18:1ω9) fractions was observed in
both PC and PE. Second, the relative level of
C18:2ω6 increased in PC, whereas the
absolute value was enhanced in PC and PE.
Third, the relative and absolute values of
C20:4ω6 tend to decrease in PC and increase
in PE. Fourth, the relative and absolute values
of C22:4ω6 and C22:5ω6 decreased in PC,
whereas only the relative value of C22:5ω6
decreased in PE. The n-3 fatty acid,
C22:6ω3, also decreased in PC but tended to
increase in PE. Fifth, both the relative and
absolute total PUFA values decreased in PC
but only the relative levels decreased in PE.
And, sixth, the P/S ratio decreased in both
PC and PE, suggesting a less fluid plasma
membrane structure. 
Mechanistic Implications with Respect
to Cancer Promotion
Apart from the role of the PUFA in regulating
many processes in the cells via their production
of different classes of prostaglandins, their role
in determining the structure and function of
cellular membranes also must be considered.
A change in saturation could determine the
responsiveness of cells to transformation or
the expression of speciﬁc phenotypes support-
ing differential growth that produces clonal
expansion of certain cell types associated with
neoplastic development. With respect to
cancer promotion, the disruption of growth-
stimulatory responses in primary hepatocytes
and regenerating liver could be important in
establishing the growth differential. 
Altered lipid parameters associated with
the growth of hepatocyte nodules. Abel et al.
(58) recently investigated the role of different
lipid parameters in the development and/or
progression of hepatocyte nodules at different
time intervals (1, 3, 6, and 9 months). The
concentration of the phospholipid PE
increased, whereas the total cholesterol
increased in the 1- and 9-month nodules.
Despite the fact that PC increased in the 1-
month nodules, the increased level of PE
caused a decrease in the PC/PE ratio in hepa-
tocyte nodules. Fatty acid analyses indicated
that C18:1ω9 and C18:2ω6 increased in PE
and PC, while C20:4ω6 decreased in PC but
increased quantitatively in PE. The end prod-
ucts of the n-6 and n-3 pathways, C22:5ω6
and C22:6ω3, decreased both qualitatively
and quantitatively in PC, causing a decrease
in PUFA. The lipid proﬁles of the surround-
ing tissue reﬂect those of the control tissue. In
regenerative liver (over 7 days after partial
hepatectomy), used as a control for cell prolif-
eration, the fatty acid proﬁles of PE and PC
are very similar to those of hepatocyte nod-
ules except that C18:1ω9 decreased in PC.
Other differences were the increased mem-
brane fluidity and the tendency of PC to
decrease in regenerating liver. Apart from a
few differences, the lipid parameters associ-
ated with increased cell proliferation in the
hepatocyte nodules closely mimic those of
normal regeneration in the liver. However,
one major difference is that the lipid changes
in the nodules are persistent whereas they are
reversed in regenerating liver. In the hepato-
cyte nodules the altered lipid metabolic pat-
tern, speciﬁcally the fatty acid proﬁles, could
be important in regulating growth in these
lesions. In this regard, the increased levels of
PE and C20:4ω6 are of interest because the
fatty acid regulates many processes related to
cell growth, such as proliferation and apopto-
sis (58). With respect to cell proliferation in
hepatocyte nodules, the role of C20:4ω6 and
its cyclooxygenase prostaglandin E2 series
products in the activation of protein kinase C
and mitogen activation protein kinases
should be considered (59). Tang et al. (60)
suggested that the metabolism of C20:4ω6 is
involved in the evolution of preneoplastic foci
into nodules and hepatocellular carcinomas in
rat liver. C20:4ω6 has also been linked to the
action of transforming growth factor
(TGF)-α and tumor necrosis factor (TNF)-α
(61), which together with the deregulation of
c-myc expression could be important determi-
nants during FB1-induced apoptosis in the
liver of rats.
The decrease in PUFA and the increase in
C18:1ω9 in hepatocyte nodules have been
suggested to play important roles in the
lower levels of lipid peroxidation normally
seen in cancerous lesions (62). Cancer cells
have low levels of PUFA and the degree of
depletion in vitro can be an accurate predictor
of its malignancy in vivo.
Disruption of growth control by FB1. The
effects of FB1 on phospholipid and fatty acid
metabolism closely mimic those seen in
hepatocyte nodules, although there are some
differences, as described for nodules and
regenerating liver (see above). The decrease in
fatty acid saturation, induced by FB1, implies
a more rigid membrane structure such as
found in hepatocyte nodules. The n-6 fatty
acid pathway is markedly affected with an
accumulation of C18:2ω6 and a decrease in
C20:4ω6 as well as in the subsequent prod-
ucts C22:4ω6 and C22:5ω6. This specific
altered fatty acid pattern (Figure 1) likely
caused an impaired ∆6 desaturase enzyme.
This hypothesis was further strengthened by
the fact that another substrate for the enzyme,
C18:1ω9, increased and an n-3 fatty acid
product of the enzyme, C22:6ω3, decreased.
However, the modulating effect of FB1 on this
rate-limiting enzyme in fatty acid metabolism
still needs to be elucidated. The decrease in
PUFA, in addition to the disruption of fatty
acid metabolism, could also result from lipid
peroxidation induced by FB1 at high-dosage
levels (45). In this regard the accumulation of
C18:1ω9 is of interest because C18:1ω9
exhibits potent antioxidant activity (62) that,
in the case of FB1-induced hepatotoxicity,
could provide a speciﬁc survival mechanism to
hepatocytes under conditions of stress. 
The concentration of PE is markedly
increased in the membrane fractions of the
hepatocyte, increasing the absolute values of
C20:4ω6 within the cell. The latter state—
together with the increased level of C18:1ω9,
which implies a lower oxidative status—is
likely to favor cell proliferation, especially in
the initiated hepatocyte cell population
(60,62). This becomes evident with a similar
fatty acid pattern found in hepatocyte nod-
ules (58), presumably sustaining cell prolifer-
ation, whereas in the surrounding and normal
liver it appears to inhibit growth, thereby cre-
ating an environment for the differential inhi-
bition of growth. This is also true for FB1,
which effects this altered lipid profile in the
liver and can inhibit cell proliferation in
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regenerating liver (16,17,33). However, in
such an environment the initiated hepato-
cytes would proliferate into hepatocyte nod-
ules, and some of these might develop into
tumors after continued exposure to FB1. Very
little is known about the nodules induced by
FB1 in the liver, but because hepatocyte nod-
ules appear to be very similar with respect to
the resistant phenotype regardless of the ini-
tiator or promoter used (26), the differential
created by FB1 is likely to promote their
growth. Changes to membrane structure and
fluidity appear to have important implica-
tions with respect to membranal processes
related to normal growth and differentiation.
In early persistent and late preneoplastic nod-
ules, the binding of EGF, lipoproteins, and
desialylated glycoproteins is markedly
reduced (63). A decreased ligand binding
might play a role in the altered responses to
external growth inhibitory and stimulatory
factors that regulate cell proliferation and
other physiologic factors in the liver. 
Modulation of growth regulatory molecules
in the liver. The molecular mechanisms
underlying FB1-induced hepatotoxicity and
carcinogenesis have not been examined in
depth. A recent study employing Northern
blot (mRNA) analysis showed increased
hepatic expression of HGF, TGF-α, and espe-
cially TGF-β1 and c-myc during short-term
feeding of FB1 (36). Immunostaining with
LC(1-30) antibody for mature TGF-β1
showed that zone 1 and 2 hepatocytes were
responsible for the increased expression of
TGF-β1. Overexpression of TGF-β1 may be
responsible for the prominent proapoptotic
effects of FB1 in the liver. The proto-oncogene
c-myc is a positive regulator of cell proliferation
that is involved in tumor progression (64,65)
and has also been implicated in TGF-β1 sig-
naling (66). Increased expression of c-myc
oncogene and TGF-β1 may cooperate in the
promotion of liver tumors during feeding FB1,
possibly by providing an environment that
selects for the growth of TGF-β1-resistant
transformed liver cells. Oncogenesis due to
overexpression of both c-myc and TGF-α
appears to involve disruption of the Rb/E2F
pathway and deregulation of cell cycle control.
Both c-myc and TGF-α contribute to induc-
tion of cyclin D1 expression and resultant
inactivation of the retinoblastoma tumor sup-
pressor protein, and c-myc may directly induce
E2F (67). With respect to apoptosis, overex-
pression of c-myc together with the depletion
of growth factors and/or disruption of growth
signaling pathways could cause imbalances of
cell cycle progression and hence induction
apoptosis (68). In this regard, FB1 overex-
pressed c-myc in rat liver (36), whereas it dis-
rupted growth-related responses in different
cell types such as primary hepatocytes (41) and
in the liver in vivo (33).
Recent evidence shows that FB1 stabilizes
cyclin D1, causing accumulation of the pro-
tein in the nucleus of altered hepatocytes in
foci, nodules, adenomas, and carcinomas (69)
in the livers of rats (male BD IX) fed FB1
over a period of two years (19). In male
Fischer rats fed FB1 over a period of 21 days
(17), cyclin D1 protein levels in liver also
increased up to 5-fold in a dose-responsive
manner, with no simultaneous increase in
mRNA. The increase in FB1-treated samples
of cyclin-dependent kinase (Cdk)4 complexes
with cyclin D1 and consequently elevated
Cdk4 activity were conﬁrmed by an increased
phosphorylation of the retinoblastoma pro-
tein. Levels of cyclin E and Cdk2 did not dif-
fer between controls and FB1-treated livers
(short term) except for one sample in which a
decrease in both proteins was detected.
Alterations in cyclin D1 were speciﬁc to the
livers, and all other tissues were negative for
cyclin D1 overexpression except the kidney.
Kidney showed some positive nuclear staining
in the proximal tubules in both untreated and
treated rats. This ﬁnding must be interpreted
with caution in view of the tendency of proxi-
mal tubules often to stain nonspecifically in
immunohistochemistry. Because chronic
interstitial nephritis was present in the kid-
neys and FB1 can have toxic effects in rat
kidneys (70), this may also reflect a role of
cyclin D1 in this pathology. To test whether
the overexpression of cyclin D1 was a com-
mon property of rat HHC, liver sections
from parafﬁn-embedded rat HCC caused by
nitroglycerin or diethylnitrosamine/pheno-
barbital (DEN/PB) (71,72) were compared
to those induced by FB1. The cyclin D1
overexpression, characteristic of FB1-induced
preneoplastic lesions and HCC, was not
changed in HCC caused by DEN/PB or
nitroglycerin. However, HCCs induced by
nitroglycerin or DEN/PB showed proliferat-
ing cell nuclear antigen staining rates similar
to those in the FB1–induced tumors. These
findings suggest that altered cyclin D1 and
Cdk4, as major cell cycle oncogenes, may be
role players in the carcinogenic effects of
FB1. Presently, we are in the process of deter-
mining which signaling molecules, known to
participate in the regulation of cyclin D1 sta-
bility/degradation, could be affected by FB1.
The modulating effects of FB1 on both
sphingolipids and phospholipids could play a
major role in the molecular events involving
cyclin D1 protein stability (69). 
Conclusions
The toxicity induced by FB1 in the liver
appears to play an important role during the
cancer initiation, and the induction of oxida-
tive damage and lipid peroxidation could be
important initial events. Selective inhibition
seems to be the likely mechanism during
cancer promotion. Changes in the balance of
the different cell regulatory molecules dis-
cussed above are likely to be involved in the
induction of a growth differential that selec-
tively stimulates the growth of initiated cells.
This was shown with the peroxisome prolifer-
ator Wy-14,643, which decreased the level of
HGF in the liver (73). In vitro studies (74)
indicate that HGF stimulates the growth of
normal hepatocytes while inhibiting the
growth of preneoplastic or neoplastic cells.
The reduction of HGF therefore could play
an important role in the promotion of pre-
neoplastic cell growth. Apoptosis is also very
important during the growth of hepatocyte
nodules because cancer promoters such as
phenobarbital are known to decrease the rate
of apoptosis in these lesions (75). FB1 can
induce apoptosis in the liver (36,49) and the
disruption of sphingolipid metabolism has
been implicated because it disrupts sphin-
golipid metabolism and therefore ceramide
synthesis (53), an important signaling
molecule for apoptosis. However, fatty acids,
especially C20:4ω6, have been found to
be important second messengers during
TNF-α–induced apoptosis by the release of
ceramide via the stimulation of sphingomyeli-
nase (61). In rat hepatoma cells, C20:4
metabolites were also shown to be involved in
apototic cell death elicited by TGF-β1 (76).
In a recent study in an esophageal cancer cell
line, C20:4ω6 and its cyclooxygenase prod-
ucts prostaglandin E2 and prostaglandin A2
induced apoptosis, a process that was inhib-
ited by FB1 (77). The effect of FB1 can be
explained either by the reduction of ceramide
or the regulation of C20:4ω6 levels, as dis-
cussed above. In contrast, a recent study indi-
cated that FB1 induced apoptosis in
esophageal epithelial cells and neonatal
human keratinocytes (51). It would appear
that, depending on the cell type, the extent to
which different pathways are interrupted
could determine whether the cell would
undergo apoptosis (78). A unique pathway
has been proposed whereby the glycerophos-
pholipids and the sphingolipid cycle interact
to control a variety of cellular processes
including apoptosis, with C20:4ω6 and
ceramide as the key role players (61). A simi-
lar interactive pathway is likely to exist for the
fumonisins in the liver to regulate processes
related to cell proliferation and apoptosis
(Figure 2). FB1 effects a similar phospholipid
and hence fatty acid pattern in the liver, as
was noted in hepatocyte nodules. However,
subsequent effects on sphingolipid and/or
prostaglandin production seems to inhibit the
growth of normal hepatocytes, which
together with the overexpression of TGFβ-1
and c-myc could effect apoptosis. Oxidative
damage and the resultant lipid peroxidative
products could also further enhance apoptosis
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in the liver (79); on the other hand, the
increased C18:1ω9 and C20:4ω6 fatty acids
and the decrease in PUFA are critical parame-
ters likely to favor cell proliferation (60,62),
especially in the initiated cell population.
The disruption of the phospholipid and
n-6 fatty acid metabolic pathway, producing
changes in the level of C20:4ω6, appears to
be critical with respect to cancer promotion,
especially at low dietary levels of FB1, where
cancer promotion is effected in the absence of
apoptosis and the disruption of the sphin-
golipid metabolic pathway. Future studies
will focus on the role of C20:4ω6 as a second
messenger molecule, including the regulation
of its release by phospholipase A2 and the
subsequent modulating effects on cell prolif-
eration and apoptosis that could eventually
cause development of the cancer phenotype
in the liver.
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Figure 2. Diagram illustrating the role of FB1 on lipid,
sphingolipid, and fatty acid metabolism as a model for
the enhanced proliferation in hepatocyte nodules (bold
arrows). Abbreviations: PLA2, phospholipase A2;
p-LPerox, products of lipid peroxidation. Inhibition of
growth of normal cells seems to be related to the dis-
ruption of the ω6 fatty acid metabolic pathway, involv-
ing the ∆6 desaturase enzyme and PGE2. Subsequent
effects regarding the growth regulation (inhibition) in
normal cells included the disruption of growth factor
responses with the induction of apoptosis, involving p-
LPerox, overexpression of c-myc/TGF-β, and the disrup-
tion of sphingolipid metabolism via the inhibition of
ceramide synthase by FB1. 
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